Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZ91HE
|
|||
| Drug Name |
OP-1250
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 1/2 | [1] | |
| Company |
Olema Pharmaceuticals; Otsuka America Pharmaceutical
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04505826) A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Olema Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.